John Ravits - Concepedia

Author

John Ravits

University of California San Diego ORCID

Also Known As

Christopher B. Brady, Ernest Fraenkel, J Ravits, J. M. Ravits, J. Ravits, JOHN RAVITS, John M Ravits, John M. Ravits, John Ravits, Josh Dubnau

179

Publications

18K

Citations

H-Index

110

Concepts

All Affiliations

University of California San Diego Harvard University Washington University in St. Louis Massachusetts General Hospital Ludwig Cancer Research

About

John Ravits is an author at University of California San Diego specializing in medicine, neurology, and neurodegenerative diseases.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	36	7K
2	Health Sciences	6	6	331
3	Natural Sciences	4	4	1.5K
4	Arts	1	1	29
5	Engineering	1	1	972

John Ravits

Publications

12.6K

Citations

H-Index

Page 1

	Year	Citations
Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with <i>SOD1</i> mutations Ian R. Mackenzie, Eileen H. Bigio, Paul G. Ince, Annals of Neurology	2007	975
Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways Elizabeth T. Cirulli, Brittany N. Lasseigne, Slavé Petrovski, Science EngineeringExome SequencingGeneticsImmunologyDisease Gene Identification	2015	972
Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs Clotilde Lagier‐Tourenne, Magdalini Polymenidou, Kasey R. Hutt, Nature Neuroscience Protein FunctionAmyotrophic Lateral SclerosisNatural SciencesAls-linked Proteins Fus/tlsMolecular Biology	2012	732
Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a <i>C9ORF72</i> Repeat Expansion Dhruv Sareen, Jacqueline G. O’Rourke, Pratap Meera, Science Translational Medicine	2013	672
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial Dan H. Moore, Robert G. Miller, Julaine Florence, The Lancet Neurology Neurodegenerative DiseasesAmyotrophic Lateral SclerosisNeurological DisorderPhase IiiNeurology	2007	637
Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration Ze’ev Melamed, Jone López‐Erauskin, Michael W. Baughn, Nature Neuroscience Neurodegenerative DiseasesTdp-43-dependent NeurodegenerationDegenerative DiseaseDegenerative PathologyNeuroprotection	2019	624
RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS Yasushi Ito, Dimitry Ofengeim, Ayaz Najafov, Science ImmunologyCell DeathNeuroinflammationInflammationAutophagy	2016	591
Targeted degradation of sense and antisense <i>C9orf72</i> RNA foci as therapy for ALS and frontotemporal degeneration Clotilde Lagier‐Tourenne, Michael W. Baughn, Frank Rigo, Proceedings of the National Academy of Sciences Neurodegenerative DiseasesAmyotrophic Lateral SclerosisSporadic AlsChromosome 9Genetics	2013	551
Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs Jie Jiang, Qiang Zhu, Tania F. Gendron, Neuron Natural SciencesAls/ftd-linked Repeat ExpansionsMolecular BiologyLong Non-coding RnaC9orf72 Is	2016	530
TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A Anna‐Leigh Brown, Oscar G. Wilkins, Matthew J. Keuss, Nature	2022	471

Page 1